Dupixent boost from FDA approval

Fol­low­ing the news that the FDA has approved Dupix­ent for the treat­ment of chron­ic rhi­nos­i­nusi­tis with nasal polyposis;

“Dupix­ent is the first bio­log­ic to be approved for the treat­ment of chron­ic rhi­nos­i­nusi­tis with nasal poly­po­sis, beat­ing rivals in gain­ing mar­ket approval and first-to-mar­ket advan­tage. Glob­al­Da­ta is fore­cast­ing that this momen­tum will see Dupix­ent reach block­buster sta­tus with $1.9bn in rev­enue in 2019 with fur­ther rev­enue growth to $6.4bn by 2025. Sanofi is build­ing on the suc­cess of Dupix­ent with its approval in a third indi­ca­tion in as many years set to boost sales fur­ther after it was approved for atopic der­mati­tis in 2017 and mod­er­ate-to-severe asth­ma in 2018.”

Philip­pa Salter, Phar­ma Ana­lyst at Glob­al­Da­ta, a data and ana­lyt­ics company